BridgeBio Pharma, Inc. Gross Margin

Gross Margin of BBIO for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.

Highlights and Quick Summary

  • Gross Margin for the quarter ending September 30, 2022 was -118.64% (a -219.78% decrease compared to previous quarter)
  • Year-over-year quarterly Gross Margin decreased by -234.88%
  • Annual Gross Margin for 2021 was 90.88% (a 45.25% increase from previous year)
  • Annual Gross Margin for 2020 was 62.57% (a -33.32% decrease from previous year)
  • Annual Gross Margin for 2019 was 93.84% (a Infinity% increase from previous year)
  • Twelve month Gross Margin ending September 30, 2022 was 95.11% (a 0.72% increase compared to previous quarter)
  • Twelve month trailing Gross Margin decreased by -0.44% year-over-year
Trailing Gross Margin for the last four month:
30 Sep '22 30 Jun '22 31 Mar '22 31 Dec '21
95.11% 94.43% 93.71% 95.53%
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of BridgeBio Pharma, Inc.

Most recent Gross Marginof BBIO including historical data for past 10 years.

Interactive Chart of Gross Margin of BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -118.64% 99.05% 20.43%
2021 87.96% 37.97% 99.8% 100.0% 90.88%
2020 100.0% 100.0% 62.57%
2019 100.0% 90.65% 93.84%
2017 0.0%

Business Profile of BridgeBio Pharma, Inc.

Sector: Healthcare
Industry: Biotechnology